Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategy
Reuters2026/08/12 21:48- Kura highlighted KOMZIFTI (ziftomenib) for adult relapsed or refractory NPM1-mutated AML, citing early launch momentum.
- 2Q 2026 KOMZIFTI net product revenue of USD 9.1 million, up 57% from 1Q; about 115 new patient starts.
- Cash and investments of USD 519 million as of June 30, 2026; USD 180 million of anticipated collaboration payments.
- Kyowa Kirin collaboration: 50/50 U.S. co-development and co-promotion; Kura books 100% U.S. sales.
- Funding expected to support the ziftomenib AML program through topline results from Phase 3 KOMET-017, anticipated in 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs: AI storage chip demand is underestimated, South Korean stock market still has 80% upside potential
Goldman Sachs Asia-Pacific Chief Equity Strategist Timothy Moe maintains a KOSPI target of 12,000 points, implying an almost 80% increase from the current level. He points out that the market is systematically underestimating the sustainability of the AI storage chip profit cycle. Capital expenditures by US tech giants may exceed $1.2 trillion next year, and the chip shortage triggered by data center expansion will further intensify in 2027. The current KOSPI is trading at only 5.3 times expected earnings, about half of its historical average.
Norwegian sovereign wealth fund may cut $80 billion US Treasury holdings; high-rated mortgage securities expected to become new favorites
Norway's sovereign wealth fund, with a scale of $2.3 trillions, has recommended reducing government bond holdings and reallocating funds towards higher-yielding fixed income assets.
Barclays names Takeo Kamai head of high-touch sales trading, Japan
Crypto prices
More
